Single Dose LSD Reduces Anxiety Without Therapy
The Trial That Stripped Everything Back
Generalised anxiety disorder affects nearly 3 per cent of adults in the United States each year. [5] It is not ordinary worry. It is excessive, persistent concern about work, relationships, health, money — a broad range of things that most people manage without clinical intervention. For those who cannot, the treatment landscape has barely shifted in decades. That stasis is the backdrop for what happened in a trial that recruited more than 200 adults across the US with moderate or severe forms of the condition.
Robert Barrow at Definium Therapeutics in New York and his colleagues designed the study around a deliberate constraint. [1] Participants were tapered off any anxiety medications before being randomly assigned to one of three groups. The first received tablets adding up to a 100-microgram dose of LSD. [5] The second received placebo pills. The third took 50 micrograms — a dose that produces mind-altering effects such as hallucinations but had not substantially reduced anxiety in a prior trial. [5] That middle group existed for a specific methodological reason: in psychedelic research, participants can usually tell whether they have taken a drug, which inflates the placebo response. The 50-microgram arm gave the trial a way to separate the drug’s therapeutic action from the mere experience of being on something.
Three months after the dosing day, those on the higher dose had experienced a 9.8-point reduction in anxiety, on average, out of 56 on a commonly used anxiety scale. The placebo group’s score dropped by 4.7 points. The difference — roughly five points on that scale — is what the trial was built to detect. None of the participants experienced severe or lasting side effects.
David Nutt at University College London, who was not involved in the trial, called the result meaningful. [2] A reduction of 9.8 points, he said, would noticeably improve someone’s quality of life. The number matters because it crosses the threshold from statistical signal to lived difference.
What distinguishes this trial from most psychedelic research is what the team deliberately withheld. Participants were not offered psychotherapy in the weeks following the dosing day. They received limited psychological support on the day itself. Those already in psychotherapy were allowed to continue, but no new therapy was added. Dan Karlin, also at Definium Therapeutics, explained the reasoning during a press briefing in August: “We stripped everything back and tried to show, to the extent we were able, the drug-only effect.” [1] The finding suggests that LSD, administered under controlled conditions without the scaffolding of talk therapy, moved anxiety scores on its own.
That assertion carries weight precisely because it contradicts the prevailing model. In most psychedelic trials for mental health conditions, psychotherapy is treated as an integral component — the drug opens a window, and therapy does the work inside it. By removing that component, the Definium team isolated a variable that had previously been entangled with everything else. The result does not prove that therapy is unnecessary. It proves that the drug is not inert without it.
The Road to the Clinic
The trial’s outcome has shifted the conversation from whether LSD can treat anxiety to when regulators will allow it. Nutt, who was not involved in the study, called the result “a milestone” and said it looks fairly likely that approval from the US Food and Drug Administration will happen in the next year or two. [2] “That would set a precedent for approval elsewhere, such as the UK and Europe,” he said. [2] The FDA’s decision would not merely affect American patients; it would establish a regulatory template that other countries could follow or adapt.
Jules Evans at the Challenging Psychedelic Experiences Project in the US, which researches difficult psychedelic experiences, offered a similar timeline. [4] “It seems likely that LSD will get FDA approved in the next 12 to 24 months,” he said. [4]
If approval comes, it will probably apply to the population the trial studied: people with moderate or severe anxiety who have tried a range of standard therapies. Nutt noted that people with milder anxiety would probably be able to access it at their doctor’s discretion. The distinction matters because it defines who the approval is for and who falls outside its formal scope. A patient with mild anxiety who has not exhausted standard treatments occupies a different category from the trial participants, who had already tried a range of therapies before entering the study.
Nutt also issued a caution that cuts against the enthusiasm the results might generate. “The results don’t mean that LSD is safe or effective to try at home,” he said. An LSD trip can last for 6 to 12 hours and can sometimes cause intense fear, panic, confusion, or frightening experiences. [4]
The screening criteria in the trial reflect that risk. Only people without a history of psychosis or suicidal thoughts and behaviour were included. Nutt described the conditions: “People were screened extremely carefully and given the drugs in an extremely well-controlled and safe and well-considered environment.” Such careful screening is needed, alongside long-term monitoring, if LSD is approved, according to Evans. Three months of follow-up data cannot answer what happens at twelve months, at two years, or after a second dose.
In rare cases, LSD can cause psychosis and suicidal thoughts and behaviour. The trial’s exclusion criteria kept those outcomes from appearing in the data, but they remain part of the drug’s profile. An approval would therefore carry an implicit obligation: the controlled conditions of the trial must be reproducible in clinical practice, or the safety record that supported approval would not hold.
Sources
1. Definium Therapeutics — Organisation (homepage)
2. University College London — Organisation (homepage)
3. US Food and Drug Administration — Organisation (homepage)
4. Challenging Psychedelic Experiences Project — Organisation (homepage)